

11 Feb 2020 | Analysis

QUOTED. 11 February 2020. Jim Mault.

by

This quarter, Denver, CO-based start-up BioIntelliSense and its strategic partner, UCHHealth, will begin clinical testing of the BioSticker, a wearable sensor designed to remotely monitor patients' vital signs that was recently cleared by the US Food and Drug Administration. See what BioIntelliSense's founder and CEO, Jim Mault, said about it here.

"The sticker can literally collect that data minute by minute, hour by hour, day after day, so we'll have much richer data at a fraction of the cost of the conventional clinical trials where you either had to send a nurse to the house or you had to pay the patient to come to the clinic to get some measurements." – Jim Mault, CEO, BioIntelliSense

- Find out more: [Start-Up Spotlight: BioIntelliSense Launches New FDA-Cleared BioSticker For Remote Monitoring Of Patients' Vital Signs](#)

[Click here](#) for a free trial of *Medtech Insight*